HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") will host a corporate update conference call at 8:00 am ET ( 5:00 am PT ) on Thursday, June 26, 2014 . The Company will review recent significant milestones, as well as progress with the Pulmaquin® program in
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 ( O nce-daily R
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") announced that it has received the $5 million milestone payment from Grifols S.A. for the dosing of the first patient in the ORBIT-3 ( O nce-daily R espiratory B ronchiectasis I nhalation T
Pulmaquin designated as a QIDP for Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Chronic Lung Infections with Pseudomonas aeruginosa HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced that the U.S.
Completion of Royalty Assignment Eliminates All Debt HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2014 . Total revenue was $6.6 million for the first quarter of
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM.OB) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-3 ( O nce-daily
HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the Oregon State University , Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the "Company") demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus , Aradigm's
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013 . Fourth Quarter 2013 Results The Company recorded $4.6 million in revenue in the fourth quarter of 2013 compared
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 16 th Annual BIO CEO & Investor Conference 2014 on Tuesday, February 11, 2014 , at 10:30 a.m. ET .
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at Biotech Showcase 2014 on Tuesday, January 14, 2014 , at 11: 30 a.m. Pacific time.
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today announced that Juergen Froehlich , MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals where he was Head of Regulatory Affairs, overseeing
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2013 . Total revenue was approximately $4.6 million for the third quarter of 2013 compared with revenue of
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced changes to its Board of Directors, including the retirement of Frank Barker and the appointment of Lafmin Morgan and David Bell . Mr.
INDIANAPOLIS & HAYWARD, Calif. --(BUSINESS WIRE)-- Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc. ), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Nancy E. Pecota , Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2013 Healthcare Conference at the Four Seasons
Aradigm's Proprietary Inhaled Antibiotic for the Chronic Therapy of Patients with Severe Respiratory Disease is Advancing Into Phase III BARCELONA, Spain & HAYWARD, Calif. --(BUSINESS WIRE)-- Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and Aradigm Corporation (OTC BB:ARDM.OB)
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2013 . Total revenue was approximately $0.2 million for both the second quarter of 2013 and the second quarter of 2012.
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Heart, Lung, and Blood Institute , National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of pulmonary non-tuberculous
Aradigm's Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced that the Company's shareholders approved all
